Protection by S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation-induced leg contractures in mice.

S-2-(3-Aminopropylamino)ethylphosphorothioic acid (WR-2721) was shown to provide marked protection against development of radiation-induced leg contractures in C3Hf/Kam mice whose legs were exposed to single doses of gamma-radiation. The radiation doses ranged from 3300 to 6200 rads delivered to the right hind thighs from two parallelly opposed 137Cs sources. WR-2721 was given i.p. 30 min before irradiation. The severity of radiation-induced leg contractures in untreated and WR-2721-treated mice was followed for 342 days after irradiation. The degree of leg contractures in both control and WR-2721-treated mice increased up to 100 days after radiation, when the change stabilized, remaining more or less at the same level to the end of the observation period. During this entire period, the severity of contractures was less in WR-2721-treated mice. The dose-modifying factor for the level of 5 mm reduction in leg extension was 1.5 at 182 days after irradiation. Since WR-2721 did not prevent the radiocurability of 8-mm fibrosarcomas growing in the same legs, these data imply that WR-2721 has a high potential for increasing therapeutic gain when combined with irradiation in the treatment of tumors of an appreciable size.

[1]  G. Fletcher,et al.  Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. , 1983, International journal of radiation oncology, biology, physics.

[2]  H. Thames,et al.  Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice. , 1982, Cancer research.

[3]  G H Fletcher,et al.  Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. , 1982, International journal of radiation oncology, biology, physics.

[4]  C. Bloor,et al.  Protection of normal tissue against late radiation injury by WR-2721. , 1981, Radiation research.

[5]  T. Phillips,et al.  Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. , 1981, Cancer clinical trials.

[6]  H. Withers,et al.  Late effect in mouse skin following single and multifractionated irradiation. , 1980, International journal of radiation oncology, biology, physics.

[7]  J. Yuhas Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. , 1980, Cancer research.

[8]  T. Phillips Rationale for initial clinical trials and future development of radioprotectors. , 1980, Cancer clinical trials.

[9]  J. Yuhas,et al.  Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. , 1980, Cancer treatment reports.

[10]  J. Yuhas,et al.  The role of WR-2721 in radiotherapy and/or chemotherapy. , 1980, Cancer clinical trials.

[11]  J. Hopewell,et al.  Late radiation damage to pig skin. , 1979, Radiology.

[12]  A. D. Conger,et al.  Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. , 1978, Radiation research.

[13]  J. Denekamp Early and late radiation reactions in mouse feet. , 1977, British Journal of Cancer.

[14]  A. J. van der Kogel,et al.  Late effects of spinal cord irradiation with 300 kV X rays and 15 MeV neutrons. , 1974, The British journal of radiology.

[15]  J. Hopewell,et al.  Excess late subcutaneous fibrosis after irradiation of pig skin, consequent upon the application of the NSD formula. , 1974, The British journal of radiology.

[16]  T. Phillips,et al.  Radiation pneumonitis: A new approach to the derivation of time‐dose factors , 1973, Cancer.

[17]  T. Phillips,et al.  Radioprotection of tumor and normal tissues by thiophosphate compounds , 1973, Cancer.